Oryzon Genomics S.A.
Символ: 0RDB.L
LSE
1.97
EURРыночная цена сегодня
-34.0078
Коэффициент P/E
-1.5775
PEG Ratio
123.58M
Капитал MRK
- 0.00%
Доходность DIV
Oryzon Genomics S.A. (0RDB-L) финансовые отчеты
Балансовый отчет
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 22.8 | 32.7 | 48.4 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0.1 | 0.4 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 4.1 | 4.3 | 3 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 26.9 | 37.1 | 51.8 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.7 | 0.8 | 0.8 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0.6 | 0.7 | 0.3 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.6 | 0.7 | 0.3 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 82.9 | 70 | 62.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 84.1 | 71.5 | 63.2 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 111 | 108.6 | 115 | |||||||||||
balance-sheet.row.account-payables | 0 | 5.4 | 3.3 | 2.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 13 | 4.7 | 5.9 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 11.1 | 15.2 | 10.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 1.6 | 1.8 | 1 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 13.3 | 17.6 | 12.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 0 | 33.3 | 27.5 | 22.2 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 3 | 3 | 3.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -13.1 | -9.2 | -4.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3.2 | 3.8 | 4.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 84.7 | 83.4 | 89.5 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 77.7 | 81.1 | 92.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 111 | 108.6 | 115 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | 77.7 | 81.1 | 92.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-debt | 0 | 24.1 | 19.9 | 16.5 | |||||||||||
balance-sheet.row.net-debt | 0 | 1.3 | -12.8 | -31.8 |
Отчет о движении денежных средств
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -3.7 | -4.5 | -5.3 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.2 | 0.2 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | 0.4 | 1.1 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0.3 | -0.1 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0.1 | 0.2 | ||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0.9 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | 3.7 | 2 | 0 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -0.2 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -15.2 | -13.1 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -15.3 | -13.3 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.7 | -4.7 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -1.1 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 9.7 | 4.1 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 9.3 | 4.7 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0.4 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | -9.9 | -15.7 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 22.8 | 22.8 | 32.7 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 22.8 | 32.7 | 48.4 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | -2 | -4.1 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -0.2 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | -2.1 | -4.3 |
Строка отчета о прибылях и убытках
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 16.8 | 12.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.5 | 0.8 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 16.3 | 11.2 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 5 | 22.1 | 18.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5 | 22.6 | 19.7 | ||||||||||||
income-statement-row.row.interest-income | 0 | 1.3 | 0 | 0 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -1.1 | -0.4 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 17.2 | -1.1 | -0.2 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 17.2 | -1.1 | -0.2 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -1.1 | -0.4 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.2 | 0.2 | 0.2 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | -20.9 | -5.9 | -8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | -3.7 | -7 | -8.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 2.5 | 2.8 | ||||||||||||
income-statement-row.row.net-income | 0 | -3.7 | -4.5 | -5.3 |
Часто задаваемые вопросы
Что такое Oryzon Genomics S.A. (0RDB.L) общие активы?
Oryzon Genomics S.A. (0RDB.L) общие активы - 111039575.000.
Какова годовая выручка предприятия?
Годовая выручка - N/A.
Какова норма прибыли компании?
Норма прибыли компании - 0.983.
Что такое свободный денежный поток компании?
Свободный денежный поток - 0.000.
Что такое норма чистой прибыли предприятия?
Норма чистой прибыли - -0.447.
Что такое общий доход компании?
Общая выручка - -1.500.
Что такое Oryzon Genomics S.A. (0RDB.L) чистая прибыль (чистый доход)?
Чистая прибыль (чистый доход) - -3705000.000.
Что такое общий долг компании?
Общий долг - 24113573.000.
Что такое операционные расходы?
Операционные расходы - 5027000.000.
Какова цифра денежных средств компании?
Денежные средства предприятия - 0.000.